Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
32.74
+0.75 (2.34%)
At close: Apr 2, 2026, 4:00 PM EDT
32.98
+0.24 (0.73%)
After-hours: Apr 2, 2026, 6:15 PM EDT
Stoke Therapeutics Revenue
In the year 2025, Stoke Therapeutics had annual revenue of $184.42M with 404.50% growth. Stoke Therapeutics had revenue of $1.40M in the quarter ending December 31, 2025, a decrease of -93.80%.
Revenue (ttm)
$184.42M
Revenue Growth
+404.50%
P/S Ratio
10.50
Revenue / Employee
$1,084,824
Employees
170
Market Cap
1.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 184.42M | 147.87M | 404.50% |
| Dec 31, 2024 | 36.56M | 27.78M | 316.34% |
| Dec 31, 2023 | 8.78M | -3.63M | -29.22% |
| Dec 31, 2022 | 12.41M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Galapagos NV | 1.31B |
| Soleno Therapeutics | 190.41M |
| Zymeworks | 105.97M |
| Viridian Therapeutics | 70.85M |
| Mesoblast | 65.38M |
| Agios Pharmaceuticals | 54.03M |
| Ocular Therapeutix | 51.95M |
| Capricor Therapeutics | 11.13M |
STOK News
- 16 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 4 weeks ago - The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - Business Wire
- 5 weeks ago - Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Business Wire
- 7 weeks ago - Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) - Business Wire
- 2 months ago - Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire
- 2 months ago - Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - PRNewsWire
- 2 months ago - Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity - Seeking Alpha
- 2 months ago - Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome - Business Wire